Novogen Engages Contract Research Organisation to Conduct Cantrixil Phase 1 Clinical Trial

Novogen Limited NVGN, announced today that it has engaged Novotech as the Contract Research Organisation (CRO) to conduct its Phase 1 clinical study for the drug candidate, Cantrixil, which will commence in 2016. This first-in-human study will investigate the safety and feasibility of Cantrixil administered via the intraperitoneal route for patients with refractory /recurrent peritoneal malignancies with malignant ascites. According to Novogen's Clinical and Regulatory Affairs Manager, Kimberley Lilischkis, PhD, the Cantrixil Phase 1 study will be weighted towards ovarian cancer patients with the selection of a gynecological oncology site. "However, patients with other cancer types will  also be eligible to enrol in this first study since early preclinical data suggests the drug candidate may benefit patients with a range of cancer types," Dr Lilischkis said. "Patients with malignant ascites have been chosen because ethically this patient group stands to receive the most benefit and face the least risk from the insertion of a peritoneal port or catheter, See full press release